“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
SHELTON, CT/ ACCESSWIRE / September 16, 2020 / NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a world leader in the progression of highly effective antiviral treatments based on a new nanomedicine platform, today announced that it has nominated a candidate clinical drug for COVID-19 remedy, bringing its COVID-19 program closer to human clinical trials.
The corporation accelerated its drug progression program for COVID-19 in order to create as soon as possible the maximum effective drug for regulatory approval for emergency use in the COVID-19 pandemic, after obtaining evidence of the concept of broad-spectrum anti. -Coronavirus efficiency of check candidates.
As a result, the Company has worked vigorously to harness the full strength of the nanomedicine nanoviricide platform® for those objectives.
A cure for a virus such as sarS-CoV-2 would require a multifaceted attack that stops (i) the virus’s ability to infect host cells and (ii) the virus’s ability to multiply internally in host cells. The platform allows a direct multipoint attack opposed to the virus that is designed to disable the virus and its ability to infect new cells. At the same time, a nanoviricide is also able to carry a payload in its “belly” (internal mcelle) that can be selected to have effects on the virus’s ability to replicate. Nanoviricide is designed to protect the payload of circulating metabolism. Therefore, the nanoviricidal platform provides a vital opportunity to expand a cure for SARS-CoV-2, which is the source of the COVID-19 pathology spectrum.
The clinical candidate selected through the corporation is known as NV-CoV-1-R. It is composed of a nanoviricide that we discover possesses a broad spectrum anti-coronavirus activity, Now known as NV-CoV-1, and rediscover encapsulated in The CORE of NV-CoV-1 NV-CoV-1 itself is designed to attack the viral remains themselves, and can also attack inflamed cells that have the virus’s S antigen protein, while avoiding general (unin infected) cells that do not. they have S. In addition protein, it is widely accepted that remdesivir attacks the virus replication cycle inside cells. Therefore, the combined attack allowed through NV-CoV-1-R on the virus can be a cure for infections and diseases, provided that the mandatory dosage point can be achieved without undue adverse effects. Human clinical trials will be required for the protection and efficacy of NV-CoV-1-R.
Redesivir is a well-known antiviral drug (developed through Gilead) that has been approved for the emergency remedy of SARS-CoV-2 or COVID-19 infection in several countries. NV-CoV-1 is a new agent used as a reemployment adjuvant in creating NV-CoV-1-R to improve overall efficiency. It is well known that remdesivir suffers from a circulating metabolism that breaks down the prodrug in its form of a nucleoaspect that is not gently phosphoryl. The company anticipates that encapsulation in NV -CoV-1 can protect the remdesivir from this immediate metabolism. If this happens, the actual point and stability of the re-division in the frame would accumulate. This buildup can lead to greater effectiveness if there are no side effects. Such an increase in efficacy, if found, would possibly also decrease the required dose of re-dividing in encapsulated form, i. e. in the form of NV-CoV-1-R. In this sense, NV-CoV-1 can be considered as an adjuvant that complements the effect of remdesivir, a known antiviral opposite sarS-CoV-2.
“This is an incredible step for society,” Anil R said. Diwan, PhD, president and ceo of the company, adding, “We looked to IND’s immediate progress that enables studies of fundamental protection pharmacology and, subsequently, human clinical progression at an accelerated schedule in those difficult times of the pandemic. »
NanoViricidesNanoViricides, Inc. (the “Company”) (www. nanoviricides. com) is a startup that creates special-purpose nanomaterials for antiviral therapy. Our top drug candidate is NV-HHV-101 with its first indication as a topical skin cream for a shingle rash remedy. Additionally, we have declared a clinical progression candidate, NV-CoV-1-R, which encapsulates it in NV-CoV-1 for the remedy of COVID-19. The Company is unable to assign a precise date for the filing of a NV-CoV-1-R IND due to its dependence on a number of external collaborators and consultants.
Lately, the company is running the necessary protection pharmacology studies and an IND application for NV-CoV-1-R. The company believes that since the reuser already has an emergency authorization, NV-CoV-1-R is most likely to be an approved drug, if the protection is comparable. Remdesivir is developed through Gilead. La company has developed NV-CoV-1-R independently.
The company intends to re-engage in an IND application with the US FDA. But it’s not the first time For the candidate drug NV-HHV-101 for shingles remedy once its COVID-19 assignment is subjected to clinical trials, depending on the availability of resources. -101 has slowed down due to the effects of recent restrictions on COVID-19 and the redefinition of priorities for COVID-19 drug progression paints.
The Company is also developing drugs for a number of viral diseases, adding oral and genital herpes, viral eye diseases by adding EKC and herpetic keratitis, H1N1 swine flu, H5N1 avian flu, seasonal flu, HIV, hepatitis C, rabies, dengue. fever and Ebola virus, among others. The NanoViricides platform generation and systems are based on TheraCour® nanomedicine generation TheraCour, which TheraCour licenses to AllExcel. NanoViricides holds an exclusive perpetual international license in this generation for various drugs with express targeting mechanisms in perpetuity for the remedy of the following human viral diseases: human immunodeficiency virus (HIV / AIDS), hepatitis B virus (HBV), virus of hepatitis C (HCV). )), Rabies, herpes simplex virus (HSV-1 and HSV-2), varicella zoster virus (VZV), influenza virus and Asian avian influenza, dengue virus, Japanese encephalitis virus, Nile virus virus and Ebola / Marburg virus. The Company has signed a memorandum of understanding with TheraCour that provides a limited license for studies and progression of human coronavirus drugs. The Company intends to download a full license and has started the process for it. The Company’s generation is based on broad, exclusive and sublicensable box licenses for drugs developed in those spaces through TheraCour Pharma, Inc. The Company’s business style is based on TheraCour Pharma Inc. ‘s generation of licenses for programs express verticals of express viruses, as established when it was founded in 2005.
This press release comprises forward-looking statements that reflect the Company’s existing expectations regarding long-term occasions. Actual occasions may also differ materially and substantially from those projected here and feature several points. Certain statements contained in this press release and other written or oral statements made through NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Stock Exchange Act. 1934 Securities Array. You deserve not to place undue reliance on forward-looking statements, as they involve risks, uncertainties and other known and unknown points that, in some cases, are beyond the control of the Company and that may also justify, and they are very likely to have an impact. vital in real effects, degrees of activity and performance. or achievements. The Company assumes no legal responsibility to publicly update or revise those forward-looking statements for any reason, or to update the reasons why the actual effects may also differ materially from those expected in such forward-looking statements, even if new data is presented to the long term. Important points that may also cause actual effects to differ materially from the Company’s expectations come with, but are not limited to, points that are disclosed in “Risk Factors” and in other documents filed through the Company. from time to time with the United States. Securities and Exchange Commission and other regulatory authorities. While it is not imaginable to expect or identify all these points, they could possibly come with the following: demonstration and evidence of the precept in preclinical trials that a nanoviricide is safe and effective; the successful progression of our candidate products; our ability to search and download regulatory approvals, adding regarding the indications we seek; the successful commercialization of our candidate products; and acceptance of the market position of our products. FDA refers to the United States Food and Drug Administration. The IND application refers to the “Investigational New Drug” application. CMC stands for “Chemistry, Manufacturing, and Controls. “
CONTACT: NanoViricides, Inc. info@nanoviricides. com
Public Relations Contact: MJ ClyburnTraDigital IRclyburn@tradigitalir. com
SOURCE: NanoViricides, Inc.
See the edition in accesswire. com: https://www. accesswire. com/606173/NanoViricides-Nominates-a-Novel-Candidate-for-Advancing-Into-Clinical-Trials-for-Treatment-of-COVID-19